Sector trading at '24e-'25e P/Es of 8.5x and 9.1x, with abating NIM, and at '23e P/BV 1.2x with normalised ROE of ~14%, still attractive. Adj. EPS up for '24e, down for '25e; we prefer SVEG & MING.
Q4e: adj. PTP of NOK 1.3bn up ~30% y-o-y, but down 2% q-o-q. New interest rate path lifts '24e adj. EPS, but lowers '25e. Have to look for new synergies to get excited: HOLD.
Fremtind Forsikring (14.8%) intends to merge with Eika Forsikring (4%). New market share size of 18.8% (#3) should be acceptable for the competition authority. Likely to make the industry even more rational - positive.
Sp1 banks are allowed to establish "new" Sp1 Markets. Gains will be moved from Q1'24e to Q4'23e and add to dividend capacity. Prefer MING and SVEG in Norway on more attractive valuation.
Q3 adj PTP +5% vs FactSet consensus and +24% vs ABGSCe. EPS up 7% for '23e (Q3 beat), -4% for '25e (share count). Attractive new combination at a fair price: HOLD.
Q3e: record high NII despite 3M NIBOR headwind. Trim volumes, fees and costs, impact both 23e and 25e negative. TP to NOK 128 (134) – stock not expensive, but we favour MING.
Adj. PTP beat of 7% vs. ABGSCe, 2% vs cons. driven by write-backs, muted by weaker costs & other income. Cons. EPS chg. likely down 1-4%, stock likely soft -1-4%
Trading at a P/E in '23e-'24e of 8.4x and 8.2x, and at a P/BV of 1.07x, with ROE of ~14%. Adj. EPS up (higher interest rates) — expect further cons. uplift. BUY.
Q1e: expect solid reports, but with a neutral risk/reward. Adj. EPS up (higher interest rates) — expect further cons. uplift. Trading in line with historical average — but record earnings